Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis b virus

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Taylor, John M ^a   Han, Ziying ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRILLIANT BLUE; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SURAMIN; COOMASSIE BRILLIANT BLUE; DRUG DERIVATIVE; FUCHSINE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAL PHOSPHATE-6-AZOPHENYL-2',4'-DISULFONIC ACID; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HOST CELL; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; CELL LINE; CHEMISTRY; INFLAMMATION; METABOLISM; RAT; VIROLOGY;

HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS;

ANIMALS; CELL LINE; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HEPATOCYTES; HUMANS; INFLAMMATION; PYRIDOXAL PHOSPHATE; RATS; RECEPTORS, PURINERGIC; RECEPTORS, PURINERGIC P2X7; RNA, VIRAL; ROSANILINE DYES; SURAMIN;

EID: 78650968191     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015784     Document Type: Article

References (49)

1. Seeger C, Zoulim F, Mason WS (2007) Hepadnaviruses. In: Knipe DM, ed. Fields Virology. Fifth ed. Philadelphia: Lippincott Williams & Wilkins. pp 2977-3030.
2. Taylor JM, Farci P, Purcell RH (2007) Hepatitis D (delta) virus. In: Knipe DM, ed. Fields Virology. Fifth ed. Philadelphia: Lippincott Williams & Wilkins. pp 3031-3046.
3. Rizzetto M, Canese MG, Arico J, Crivelli O, Bonino F, et al. (1977) Immunofluorescence detection of a new antigen-antibody system associated to the hepatitis B virus in the liver and in the serum of HBsAg carriers. Gut 18: 997-1003.
4. Urban S (2008) New insights into hepatitis B and hepatitis delta virus entry. Future Virol 3: 253-264.
5. Petcu DJ, Aldrich CE, Coates L, Taylor JM, Mason WS (1988) Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology 167: 385-392.
6. Schulze A, Gripon P, Urban S (2007) Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46: 1759-1768.
7. Croon JJ, Wolff HL (1982) The inhibition of yellow fever virus multiplication by suramin: a preliminary note. Acta Leiden 48: 5-8.
8. Balzarini J, Mitsuya H, De Clercq E, Broder S (1986) Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). Int J Cancer 37: 451-457.
9. Aguilar JS, Rice M, Wagner EK (1999) The polysulfonated compound suramin blocks adsorption and lateral diffusion of herpes simplex virus type-1 in vero cells. Virology 258: 141-151.
10. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP (2008) Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem 8: 1384-1394.
11. Fleck SL, Birdsall B, Babon J, Dluzewski AR, Martin SR, et al. (2003) Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum. J Biol Chem 278: 47670-47677.
12. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82: 1013-1067.
13. Burnstock G (2007) Physiology and pathophysiology of purinergic neurotrans-mission. Physiol Rev 87: 659-797.
14. Lenertz LY, Wang Z, Guadarrama A, Hill LM, Gavala ML, et al. (2010) Mutation of putative N-linked glycosylation sites on the human nucleotide receptor P2X7 reveals a key residue important for receptor function. Biochemistry 49: 4611-4619.
15. Kim M, Jiang LH, Wilson HL, North RA, Surprenant A (2001) Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J 20: 6347-6358.
16. Qu Y, Dubyak GR (2009) P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways. Purinergic Signal 5: 163-173.
17. Shehnaz D, Torres B, Balboa MA, Insel PA (2000) Pyridoxal-phosphate-6-azophenyl-29,49-disulfonate (PPADS), a putative P2Y(1) receptor antagonist, blocks signaling at a site distal to the receptor in Madin-Darby canine kidney-D(1) cells. J Pharmacol Exp Ther 292: 346-350.
18. Jiang LH, Mackenzie AB, North RA, Surprenant A (2000) Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 58: 82-88.
19. Friedle SA, Curet MA, Watters JJ (2010) Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat CNS Drug Discov 5: 35-45.
20. Anderson CM, Nedergaard M (2006) Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons. Trends Neurosci 29: 257-262.
21. Browne LE, Jiang LH, North RA. New structure enlivens interest in P2X receptors. Trends Pharmacol Sci 31: 229-237.
22. Stokes L, Jiang LH, Alcaraz L, Bent J, Bowers K, et al. (2006) Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br J Pharmacol 149: 880-887.
23. Chai N, Gudima S, Chang J, Taylor J (2007) Immunoadhesins containing preS domains of hepatitis B virus large envelope protein are secreted and inhibit virus infection. J Virol 81: 4912-4918.
24. Leistner CM, Gruen-Bernhard S, Glebe D (2008) Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 10: 122-133.
25. Johannsdottir HK, Mancini R, Kartenbeck J, Amato L, Helenius A (2009) Host cell factors and functions involved in vesicular stomatitis virus entry. J Virol 83: 440-453.
26. Michel AD, Ng SW, Roman S, Clay WC, Dean DK, et al. (2009) Mechanism of action of species-selective P2X(7) receptor antagonists. Br J Pharmacol 156: 1312-1325.
27. Peng W, Cotrina ML, Han X, Yu H, Bekar L, et al. (2009) Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA 106: 12489-12493.
28. Chiao CW, Tostes RC, Webb RC (2008) P2X7 receptor activation amplifies lipopolysaccharide-induced vascular hyporeactivity via interleukin-1 beta release. J Pharmacol Exp Ther 326: 864-870.
29. Barrera A, Guerra B, Lee H, Lanford RE (2004) Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes. J Virol 78: 5233-5243.
30. Gudima S, He Y, Meier A, Chang J, Chen R, et al. (2007) Assembly of hepatitis delta virus: particle characterization, including the ability to infect primary human hepatocytes. J Virol 81: 3608-3617.
31. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, et al. (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99: 15655-15660.
32. Burnstock G, Fredholm BB, North RA, Verkhratsky A (2010) The birth and postnatal development of purinergic signalling. Acta Physiol (Oxf) 199: 93-147.
33. Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157: 1203-1214.
34. Verhoef PA, Estacion M, Schilling W, Dubyak GR (2003) P2X7 receptor-dependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 beta release. J Immunol 170: 5728-5738.
35. Mercer J, Helenius A (2009) Virus entry by macropinocytosis. Nat Cell Biol 11: 510-520.
36. Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder S (2005) Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun 332: 17-27.
37. Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Goldberg H, et al. (2007) A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 175: 360-366.
38. Amstrup J, Novak I (2003) P2X7 receptor activates extracellular signal-regulated kinases ERK1 and ERK2 independently of Ca2+ influx. Biochem J 374: 51-61.
39. Schulze A, Schieck A, Ni Y, Mier W, Urban S (2009) Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 84: 1989-2000.
40. Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, et al. (2007) The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond) 4: 5.
41. Emmett DS, Feranchak A, Kilic G, Puljak L, Miller B, et al. (2008) Characterization of ionotrophic purinergic receptors in hepatocytes. Hepatology 47: 698-705.
42. Rassendren F, Buell GN, Virginio C, Collo G, North RA, et al. (1997) The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 272: 5482-5486.
43. Kawamura H, Aswad F, Minagawa M, Govindarajan S, Dennert G (2006) P2X7 receptors regulate NKT cells in autoimmune hepatitis. J Immunol 176: 2152-2160.
44. Carroll WA, Donnelly-Roberts D, Jarvis MF (2009) Selective P2X(7) receptor antagonists for chronic inflammation and pain. Purinergic Signal 5: 63-73.
45. Gripon P, Cannie I, Urban S (2005) Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 79: 1613-1622.
46. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Canc Res 42: 3858-3863.
47. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, et al. (1997) Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblas-toma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41: 1715-1720.
48. Glebe D, Urban S (2007) Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 13: 22-38.
49. Loeb KR, Jerome KR, Goddard J, Huang M, Cent A, et al. (2000) High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 32: 626-629.